This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vlachoyiannopoulos, P. G. Articles by Moutsopoulos, H. M. Search for Related Content PubMed PubMed Citation Articles by Vlachoyiannopoulos, P. G. Articles by Moutsopoulos, H. M. Social Bookmarking                   What's this?

Systemic Lupus Erythematosus in Greece. Clinical Features, Evolution and Outcome: a Descriptive Analysis of 292 Patients

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioamima, Greece

Fotini B. Karassa

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioamima, Greece

Kostas X. Karakostas

Department of Mathematics, School of Natural Sciences, University of Ioannina, Ioamima, Greece

Alexandros A. Drosos

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioamima, Greece

Haralampos M. Moutsopoulos

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioamima, Greece

The purpose of this study was the descriptive analysis of patients with systemic lupus erythematosus (SLE) with a particular focus on initial clinical features, evolution and outcome of disease, prevalence of clinical and serological manifestations and identification of clinicoserological associations indicative of renal and CNS involvement. The methodology applied was the following: retrospective analysis of the clinical charts of 292 unselected patients (246 female (84.2%) and 46 male (15.7%)) with SLE examined between 1982 and 1992. Multivariate analysis and hierarchical log linear models were used to examine for clinicoserological associations. Descriptive analysis was based on the prevalence of main clinicoserological features and disease outcome. The outcome was examined on the basis of the number of flares, the presence of chronic renal failure, the presence of central nervous system (CNS) involvement with subsequent disability and deaths. Flares were considered the severe alterations in disease status, requiring additional therapy to be controlled. The disease begins most frequently in the second and third decade of life with cutaneous and joint manifestations, while renal and CNS involvement developed later. The prevalence of serious renal, pulmonary and CNS involvement as well as the prevalence of RF, anti-Sm and anti-nRNP antibodies remain low. Multivariate analysis revealed the associations of renal involvement with leukopenia and serositis, of anti-Sm with leukopenia, of secondary Sjogren's syndrome with RF and of thromboembohc events with anticardiolipin antibodies. Patients with childhood onset SLE have a higher tendency for developing renal involvement than adult onset SLE patients. In addition, anti-Ro(SSA) antibodies were associated with anti-La(SSB) and RF, while anti-Sm antibodies were associated with anti-nRNP and RF. Flares occurred with a frequency of 0.07 per patient per year. Only 63.6% of flares were accompanied by positive anti-dsDNA reactivities. Reported deaths were 0.0047 per patient per year. Hierarchical log linear models indicated that the main variables of the disease were sufficient to describe our disease model and that the arder of the interaction between the variables was insignificant. We conclude that the prevalence of various clinical features associated with SLE is similar, although the prevalence of CNS and pulmonary involvement as well as anti-Sm and anti-nRNP antibodies are less prominent in Greek SLE patients than that reported in the literature. The various clinicaseralogical associations detected do not appear to be of major significance as they are not powerful enough to subgroup the disease.

Key Words: SLE • Flares • Outcome • Anti-dsDNA • Evolution

Lupus, Vol. 2, No. 5, 303-312 (1993)
DOI: 10.1177/096120339300200505


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Evangelopoulos, S Toumanidis, D Sotou, C Evangelopoulos, M Mavrikakis, M Alevizaki, and M. Dimopoulos Mitral valve prolapse in young healthy individuals. An early index of autoimmunity? Lupus, April 1, 2009; 18(5): 436 - 440. [Abstract] [PDF]

				F. G. Joseph, G. A. Lammie, and N. J. Scolding CNS lupus: A study of 41 patients Neurology, August 14, 2007; 69(7): 644 - 654. [Abstract] [Full Text] [PDF]

				S. Chaiamnuay, A. M Bertoli, J. M Roseman, G. McGwin, M. Apte, S. Duran, L. M Vila, J. D Reveille, and G. S Alarcon African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV) Ann Rheum Dis, May 1, 2007; 66(5): 618 - 622. [Abstract] [Full Text] [PDF]

				M Ishii, Y Muramoto, H Kosaka, S Ohshima, T Mima, Y Katada, S Hirohata, and Y Saeki A serological switching from anti-dsDNA to anti-Sm antibodies coincided with severe clinical manifestations of systemic lupus erythematosus (hemophagocytosis, profundus and psychosis) Lupus, January 1, 2007; 16(1): 67 - 69. [PDF]

				S Giannouli, M Voulgarelis, P D Ziakas, and A G Tzioufas Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment Ann Rheum Dis, February 1, 2006; 65(2): 144 - 148. [Abstract] [Full Text] [PDF]

				E Kassi, P G Vlachoyiannopoulos, A Kominakis, H Kiaris, H M Moutsopoulos, and P Moutsatsou Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk? Lupus, May 1, 2005; 14(5): 391 - 398. [Abstract] [PDF]

				M Ramos-Casals, M T Campoamor, A Chamorro, G Salvador, S Segura, J C Botero, J Yague, R Cervera, M Ingelmo, and J Font Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients Lupus, October 1, 2004; 13(10): 777 - 783. [Abstract] [PDF]

				I E A Hoffman, I Peene, L Meheus, T W J Huizinga, L Cebecauer, D Isenberg, K De Bosschere, F Hulstaert, E M Veys, and F De Keyser Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus Ann Rheum Dis, September 1, 2004; 63(9): 1155 - 1158. [Abstract] [Full Text] [PDF]

				R Tunc, M S Gonen, O Acbay, V Hamuryudan, and H Yazici Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study Ann Rheum Dis, May 1, 2004; 63(5): 575 - 577. [Abstract] [Full Text] [PDF]

				C P Mavragani and H M Moutsopoulos Lupus nephritis: current issues Ann Rheum Dis, September 1, 2003; 62(9): 795 - 798. [Full Text] [PDF]

				S Bujan, J Ordi-Ros, J Paredes, M Mauri, L Matas, J Cortes, and M Vilardell Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients Ann Rheum Dis, September 1, 2003; 62(9): 859 - 865. [Abstract] [Full Text] [PDF]

				M R Arbuckle, J A James, G J Dennis, M V Rubertone, M T McClain, X R Kim, and J B Harley Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus Lupus, February 1, 2003; 12(2): 99 - 106. [Abstract] [PDF]

				P V Voulgari, P Katsimbri, Y Alamanos, and A A Drosos Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature Lupus, November 1, 2002; 11(11): 722 - 729. [Abstract] [PDF]

				G S Cooper, C G Parks, E L Treadwell, E W St Clair, G S Gilkeson, P L Cohen, R A S Roubey, and M A Dooley Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States Lupus, March 1, 2002; 11(3): 161 - 167. [Abstract] [PDF]

				J M Sabio, J D Mediavilla, C Fernandez-Torres, L Aliaga, and J Jimenez-Alonso Risk factors related to hypertension in a Spanish systemic lupus erythematosus cohort Lupus, June 1, 2001; 10(6): 451 - 452. [PDF]

				P. G Vlachoyiannopoulos, U. G Dafni, I. Pakas, M. Spyropoulou-Vlachou, C. Stavropoulos-Giokas, and H. M Moutsopoulos Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele Ann Rheum Dis, May 1, 2000; 59(5): 359 - 367. [Abstract] [Full Text]

				F.B. KARASSA, J.P.A. IOANNIDIS, G. TOULOUMI, K.A. BOKI, and H.M. MOUTSOPOULOS Risk factors for central nervous system involvement in systemic lupus erythematosus QJM, March 1, 2000; 93(3): 169 - 174. [Abstract] [Full Text] [PDF]

				M. Voulgarelis, S. I G Kokori, J. P A Ioannidis, A. G Tzioufas, D. Kyriaki, and H. M Moutsopoulos Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin Ann Rheum Dis, March 1, 2000; 59(3): 217 - 222. [Abstract] [Full Text]

				M. Kitsanou, E. Andreopoulou, M. K Bai, M. Elisaf, and A. A Drosos Extensive lymphadenopathy as the first clinical manifestation in systemic lupus erythematosus Lupus, February 1, 2000; 9(2): 140 - 143. [Abstract] [PDF]

				J C Nossent and A J. Swaak Systemic lupus erythematosus VII: frequency and impact of secondary Sjogren's syndrome Lupus, May 1, 1998; 7(4): 231 - 234. [Abstract] [PDF]

				A. Al-Mekaimi, A. Malaviya, F. Serebour, I. Umamaheswaran, R. Kumar, K. Al-Saeid, and P. Sharma Serological characteristics of systemic lupus erythematosus from a hospital-based rheumatology clinic in Kuwait Lupus, January 1, 1997; 6(8): 668 - 674. [Abstract] [PDF]

				A. Malaviya, A. Chandrasekaran, A. Kumar, and P. Shamar Occasional Series Lupus Around the World Systemic lupus erythematosus in India Lupus, January 1, 1997; 6(9): 690 - 700. [Abstract] [PDF]